1349.HK logo
HKSE · 1349.HKDrug Manufacturers - Specialty & GenericUpdated Nov 8, 2026

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. P/E ratio

Current valuation, historical context, and peer comparisons.

Current P/E ratio

N/M

No meaningful positive P/E available.

Share price2.385
÷
Earnings per share-0.1318

Price and EPS in quote currency. Calculation details

Zero or negative earnings do not produce a meaningful conventional P/E.

P/E over time

2016 – 2025
Annual P/ESelected-period average 186.34×
3-year average142.09×2 positive annual observations
5-year average104.73×4 positive annual observations
10-year average186.34×9 positive annual observations
Peer median · TTM31.11×5 peers with positive P/E

Historical P/E ratios

Annual period-end data · 22 observations

1349.HK annual P/E history, newest first
Period endP/EChange
Dec 31, 2025N/MN/M
Dec 31, 2024200.26×+138.7%
Dec 31, 202383.91×+30.6%
Dec 31, 202264.23×-8.9%
Dec 31, 202170.50×-30.7%
Dec 31, 2020101.71×-31.3%
Dec 31, 2019148.00×-52.0%
Dec 31, 2018308.33×-32.0%
View all 22 annual observations +
1349.HK annual P/E history, newest first
Period endP/EChange
Dec 31, 2017453.43×+83.8%
Dec 31, 2016246.67×-6.7%
Dec 31, 2015264.29×-7.1%
Dec 31, 2014284.62×-23.1%
Dec 31, 2013370.00×-25.1%
Dec 31, 2012493.99×-42.1%
Dec 31, 2011852.53×-88.0%
Dec 31, 20107115.38×N/M
Dec 31, 2009N/MN/M
Dec 31, 2008N/MN/M
Dec 31, 2007N/MN/M
Dec 31, 2006N/MN/M
Dec 31, 2005N/MN/M
Dec 31, 2004N/MN/M

Change is relative to the preceding observation. N/M values are excluded from averages.

How 1349.HK compares

Company P/E vs. peer trailing-12-month ratios

P/E comparison with 1349.HK and provider-selected peers
CompanyP/E ratio
1349.HK logo
1349.HK This stockShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
N/M
0950.HK logo
0950.HKLee's Pharmaceutical Holdings Limited
3.75×
8049.HK logo
8049.HKJilin Province Huinan Changlong Bio-pharmacy Company Limited
4.50×
2898.HK logo
2898.HKSunho Biologics, Inc.
N/M
2500.HK logo
2500.HKVenus Medtech (Hangzhou) Inc.
N/M
6639.HK logo
6639.HKArrail Group Limited
31.11×
0383.HK logo
0383.HKTian An Medicare Limited
100.60×
1846.HK logo
1846.HKEuroEyes International Eye Clinic Limited
285.71×
6628.HK logo
6628.HKTranscenta Holding Limited
N/M

Peers are selected by the data provider. Business models and earnings definitions can differ.

Put the numbers in context

What does 1349.HK’s P/E tell you?

01

Start with its own history

Compare positive annual observations to understand how this company has been priced over time. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

02

Compare like with like

The median of the 5 positive peer ratios above is 31.11×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.

03

Check what drives earnings

One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.

Keep your research connected

Take 1349.HK into your spreadsheet

Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.

Explore Wisesheets
Quarterly P/E · latest quarter
=WISE("1349.HK", "PE Ratio", "LQ")
LQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data

Sources & calculation methodology

Current P/E

A conventional P/E is not meaningful when earnings are zero or negative. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 8, 2026; this is not a real-time trading quote.

History & averages

Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.

Data definitions and limitations

The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.

1349.HK P/E ratio: common questions

The essentials behind the numbers.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. does not currently have a meaningful positive P/E in the quote data. A zero or negative EPS makes the conventional P/E unsuitable for comparison.

Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.

N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.

Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.

Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.

Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.